Activity of BAY y 3118, a novel 4-quinolone, against Brucella melitensis.
We have tested the in-vitro activities of BAY y 3118, a new chlorofluoroquinolone, ciprofloxacin, sparfloxacin, streptomycin, tetracycline and rifampin against 59 strains of Brucella melitensis. BAY y 3118 (MIC90 0.12 mg/L) was twice as active as sparfloxacin and tetracycline (MIC90 0.25 mg/L). The activity of ciprofloxacin, rifampin and streptomycin (MIC90 0.5, 2, and 8 mg/L, respectively) was, respectively, four-, sixteen-, and more than sixty-fold lower than that of BAY y 3118.
García-Rodríguez
J A
JA
Department of Microbiology and Parasitology, Hospital Clinico Universitario, Facultad de Medicina, Salamanca, Spain.
García-Sánchez
J E
JE
Trujillano-Martín
I
I
García-Sánchez
E
E
García-García
M I
MI
Fresnadillo
M J
MJ
D000890:Anti-Infective Agents / Q000494:pharmacology*; D017347:Brucella melitensis / Q000187:drug effects*; D002006:Brucellosis / Q000382:microbiology; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C079807:Bay Y3118